Skip to content
Precision for Medicine
iStock-1500823492 (1) iStock-1500823492 (1)

Streamline Your Study Start Up with Precision

Kickstart your clinical trials with efficiency and expertise.
In today’s fast-paced clinical trial environment, initiating your study effectively is more critical than ever. Precision's approach to Study Start Up combines technological innovation, regulatory insight, and global expertise to optimize every phase of trial initiation, ensuring your study begins with the momentum needed to succeed.
iStock-1332002332 (1) (1)

Accelerating your clinical trial start up

Successful clinical trials begin with a well-executed study start up. By focusing on strategic site selection and swift regulatory submissions,  Precision’s global study start up team helps set the foundation for timely and successful trial outcomes. Our team delivers site activation with precision by leveraging locally dedicated staff and through close partnership with our Regulatory Affairs department. Through this synergy, we streamline submissions across North America, Europe, and Asia Pacific. Every study presents its own unique challenges therefore it's critical to work with seasoned staff dedicated to guiding effective study start up.
5 Average years of start up experience
45 countries supported by Precision’s Start Up team

Our Proven Pathway to Study Start Up Success

Precision's study start up services are built on a foundation of detailed planning and proactive strategy. From identifying the most suitable sites worldwide to navigating the complexities of local and global regulations, our team ensures your study is initiated without delay. With a focus on cross-functional collaboration, accountability, and proactive risk management, we partner with you to accelerate patients' access to life-changing therapies.
The Precision path

Expert perspectives from Precision

Gain new insights and strategies from our experts at the forefront of clinical and translational research.

Read: From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials

Translational Research - Biomarkers

From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1748379090824, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716212769184, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=51739740}, second={hs_id=182710436924, hs_child_table_id=0, hs_updated_at=1731419754428, hs_published_at=1748379090824, description=Christie Bongel, MS, CT(ASCP), brings nearly two decades of experience in both research and clinical medicine. As the site director for Precision for Medicine’s IHC Center of Excellence in North Carolina, she excels in managing scientific operations and collaborating with clients. Christie is skilled in cytology, laboratory medicine, and molecular diagnostics. Her role focuses on building an energized team dedicated to delivering life-changing outcomes for patients. Christie earned her MS in Applied Biotechnology and is an ASCP certified cytotechnologist., avatar=Image{width=260,height=260,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christie%20Bongel_Square_260px.jpg',altText='Christie Bongel_Square_260px',fileId=178044303113}, lastname= Bongel, hs_initial_published_at=1731517828480, hs_created_by_user_id=28386183, hs_created_at=1731419696820, hs_is_edited=false, hs_deleted_at=0, name=Christie, job=Site Director - Histology, slug=christie-bongel, hs_updated_by_user_id=51739740}, third={}})
  • Deborah P. avatar

    Deborah P.

  • Christie  . avatar

    Christie .

Discover
Read: Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites

Clinical Trials - Oncology - Rare Diseases

Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1748379090824, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover
Read: Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

Clinical Trials - Oncology - Cell Therapies

Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1748379090824, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover
  • Discover Early Phase Excellence
    82 (1)

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy

    Explore
  • Discover Late Phase Success
    late-phase

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.

    Explore

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore